期刊文献+

非诺贝特致不良反应分析 被引量:7

Analysis Literature of Fenotibrate-Induced ADRS
原文传递
导出
摘要 目的探讨非诺贝特致药品不良反应(ADRs)的一般规律和特点。方法检索PubMed(1978年-2009年8月)、中国期刊全文数据库CNKI(1980年-2009年8月)、中国生物医学文献数据库CBMDise(1980年-2009年8月)非诺贝特所致ADRs文献,进行统计、分析。结果非诺贝特致ADRs多发生在>40岁年龄段,与性别无显著关联;64例ADRs主要涉及骨骼肌肉系统、消化系统、泌尿生殖系统、过敏反应,及时处理者预后良好。结论临床上应重视非诺贝特所致ADRs,及时处理。 Objective To analyse the clinical features,correlation factors,preventions and cures of ( adverse drug reactions,ADRs) caused by fenofibrate. Methods The cases of ADRs caused by fenofibrate were collected and analyzed from Pubmed ( 1978 -August 2009) ,CNKI ( 1980 -August 2009) and CBMDise ( 1980 -August 2009). Results Fenofibrate-induced ADRs were mostly seen in patients over 40 years old,but which was independent for sex. Totally,64 ADRs were involved in the skeletal musculature system,digestive system,urinogenital system,and allergic response. The prognosis was favorable. Conclusion More attention should be given to patients with fenofibrate and ADRs should be treated as soon as possibile.
出处 《华西医学》 CAS 2010年第8期1536-1538,共3页 West China Medical Journal
关键词 非诺贝特 不良反应 文献分析 Fenofibrate Adverse drug reactions Literature analysis
  • 相关文献

参考文献6

二级参考文献14

  • 1戴波.非诺贝特致横纹肌损伤一例[J].中国循环杂志,2000,15(6):327-327.
  • 2Hodel Christian. Myopathy and rhabdomyolysis with lipidlowering drugs.Toxicol - Lett,2002,128( 1 - 3) : 159 - 168.
  • 3Roberts WC. Safety of fenofibrate-US and worldwide experience.Cardiology, 1959, 76:169 - 179.
  • 4Barker BJ, Goodenough RR, Falko JM. Fenofibrate monotherapy induced rhabdomyolysis. Diabetes Care, 2003, 26:2482 - 2483.
  • 5Guay DR. Micronized fenofibrate : a new fibric acid hypolipidemic agent. Ann Pharmacother, 1999, 33 : 1083 - 1103.
  • 6Spence JD, Munoz CE, Hendricks L, et al. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol, 1995, 76 :80 - 83.
  • 7Adkins JC, Faulds D. Micronised fenofibrate:a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs, 1997, 54 : 615 - 633.
  • 8Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. Am J Cardiol, 2004, 94:935 - 938.
  • 9Massy ZA, Ma JZ, Louis TA. Lipid-lowering therapy in patients with renal disease. Kidney Int, 1995, 48:188 - 198.
  • 10Schlienger JL, Goichot B, Grunenberger F, et al. Thyroid myopathy disclosed by a fibrate. Rev Med Interne, 1997, 18:169 - 170.

共引文献76

同被引文献62

引证文献7

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部